PNC Financial Services Group’s UroGen Pharma URGN Stock Holding History

PNC Financial Services Group’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5K	Buy	68 +5	+8%	+$135	﹤0.01%	4606
2026 Q1	$1.13K	Hold	63	–	–	﹤0.01%	4729
2025 Q4	$1.48K	Buy	63 +34	+117%	+$738	﹤0.01%	4599
2025 Q3	$579	Buy	29 +7	+32%	+$126	﹤0.01%	4778
2025 Q2	$301	Buy	+22	New	+$211	﹤0.01%	4755
2024 Q4	–	Sell	-500	Closed	-$6.35K	–	4927
2024 Q3	$6.35K	Hold	500	–	–	﹤0.01%	3969
2024 Q2	$8.39K	Sell	500 -43	-8%	-$612	﹤0.01%	3835
2024 Q1	$8.14K	Buy	543 +542	+54,200%	+$8.86K	﹤0.01%	3814
2023 Q4	$15	Buy	+1	New	+$13	﹤0.01%	4603

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

PNC Financial Services Group's URGN Position: Q2 2026 in Review

PNC Financial Services Group increased its UroGen Pharma (URGN) stake by 7.9% in Q2 2026, buying an estimated $135 and bringing the position to 68 shares worth $2.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4606.

PNC Financial Services Group first reported a position in URGN in Q4 2023 and has held it in 9 quarters since. The position peaked at $8.39K in Q2 2024. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

PNC Financial Services Group held 68 shares of UroGen Pharma worth $2.5K as of Q2 2026.
PNC Financial Services Group bought 5 UroGen Pharma shares in Q2 2026, an estimated $135.
UroGen Pharma made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4606 holding.
PNC Financial Services Group first reported a position in UroGen Pharma in Q4 2023 and has held it in 9 quarters since.
PNC Financial Services Group's UroGen Pharma position peaked at $8.39K in Q2 2024.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.